SCHEMBL313894

SCHEMBL313894

CCCCCCCCC(O)C(O)CO

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.65
CYP2D6 P10635 2/20 0.65
SPHK1 Q9NYA1 2/20 0.65
GMNN O75496 1/20 0.65
POLB P06746 1/20 0.65
THPO P40225 1/20 0.65
MTOR P42345 1/20 0.65
BLM P54132 1/20 0.65
KDM4E B2RXH2 1/20 0.65
TP53 P04637 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
MAPT P10636 1/20 0.65
CETP P11597 1/20 0.65
HTT P42858 1/20 0.65
UBE2N P61088 1/20 0.65
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ASAH1 Q13510 1/20 0.49
GPR84 Q9NQS5 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796385 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1964586 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL4287325 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL2312898 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL10571108 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL25243382 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL2233834 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL918858 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1964037 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL918041 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12539313-B2 Microbial removal CAPRETTO EHF. (IS) 2026-02-03 US claimed
EP-4659733-A1 BACTERICIDAL AND PRESERVATIVE COMPOSITION Bjbiochem Co., Ltd. (KR) 2025-12-10 EP claimed
EP-3934753-B1 MICROBIAL REMOVAL CAPRETTO EHF (IS) 2025-11-05 EP claimed
US-12396941-B2 Cosmetic composition that resists pilling L'OREAL (FR) 2025-08-26 US claimed
US-12303576-B2 Two phase water-based smudge-resistant make-up remover L'OREAL (FR) 2025-05-20 US claimed
CN-119923268-A Neem leaf extract 劳伦茨·沃尔德维尔贝克 2025-05-02 CN claimed
WO-2024162523-A1 BACTERICIDAL AND PRESERVATIVE COMPOSITION 주식회사 비제이바이오켐 2024-08-08 WO claimed
WO-2024162594-A1 BACTERICIDAL AND PRESERVATIVE COMPOSITION 주식회사 비제이바이오켐 2024-08-08 WO claimed
US-20240245051-A1 DISINFECTING, ANTIMICROBIAL AND PRESERVATIVE COMPOSITION BJBIOCHEM CO., LTD. (KR) 2024-07-25 US claimed
CN-118217453-A Hyaluronic acid epidermis filling preparation and preparation method thereof 湖南湘妃医疗器械有限公司 2024-06-21 CN claimed
EP-0507337-A2 Novel erucyl, brassidyl and nervonyl derivatives Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1992-10-07 EP claimed
EP-0248062-B1 MEDICAMENTS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1992-05-06 EP claimed
EP-0248047-B1 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1991-06-19 EP claimed
US-4837023-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) 1989-06-06 US claimed
EP-0248047-A1 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE. MAX PLANCK GESELLSCHAFT (DE) 1987-12-09 EP claimed
EP-0248062-A1 MEDICAMENTS. MAX PLANCK GESELLSCHAFT (DE) 1987-12-09 EP claimed
EP-0230575-A2 Medicament active against tumours, containing hexadecylphosphocholine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-08-05 EP claimed
WO-1987003480-A2 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO claimed
WO-1987003478-A2 MEDICAMENTS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO claimed
EP-0225608-A2 Medicine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539313-B2 Microbial removal CUTA, MIF, PCNA LMNA 2232/4885CYP2D6 1344/4885SPHK1 2941/4885
US-20240245051-A1 DISINFECTING, ANTIMICROBIAL AND PRESERVATIVE COMPOSITION CUTA, WASHC5, POLR1C LMNA 2742/4885CYP2D6 1572/4885SPHK1 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.